These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9298754)

  • 1. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.
    Schols D; Esté JA; Henson G; De Clercq E
    Antiviral Res; 1997 Aug; 35(3):147-56. PubMed ID: 9298754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
    Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
    J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.
    Schols D; Esté JA; Cabrera C; De Clercq E
    J Virol; 1998 May; 72(5):4032-7. PubMed ID: 9557691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
    Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
    Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication.
    Egberink HF; De Clercq E; Van Vliet AL; Balzarini J; Bridger GJ; Henson G; Horzinek MC; Schols D
    J Virol; 1999 Aug; 73(8):6346-52. PubMed ID: 10400726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
    De Clercq E
    Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
    Moncunill G; Armand-Ugón M; Clotet-Codina I; Pauls E; Ballana E; Llano A; Romagnoli B; Vrijbloed JW; Gombert FO; Clotet B; De Marco S; Esté JA
    Mol Pharmacol; 2008 Apr; 73(4):1264-73. PubMed ID: 18182480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.
    Willey SJ; Reeves JD; Hudson R; Miyake K; Dejucq N; Schols D; De Clercq E; Bell J; McKnight A; Clapham PR
    J Virol; 2003 Jun; 77(11):6138-52. PubMed ID: 12743271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
    Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells.
    Schols D; De Clercq E
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2203-5. PubMed ID: 9747729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
    Zhang Y; Lou B; Lal RB; Gettie A; Marx PA; Moore JP
    J Virol; 2000 Aug; 74(15):6893-910. PubMed ID: 10888629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
    Oberlin E; Amara A; Bachelerie F; Bessia C; Virelizier JL; Arenzana-Seisdedos F; Schwartz O; Heard JM; Clark-Lewis I; Legler DF; Loetscher M; Baggiolini M; Moser B
    Nature; 1996 Aug; 382(6594):833-5. PubMed ID: 8752281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
    Esté JA; Cabrera C; De Clercq E; Struyf S; Van Damme J; Bridger G; Skerlj RT; Abrams MJ; Henson G; Gutierrez A; Clotet B; Schols D
    Mol Pharmacol; 1999 Jan; 55(1):67-73. PubMed ID: 9882699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.
    de Vreese K; Kofler-Mongold V; Leutgeb C; Weber V; Vermeire K; Schacht S; Anné J; de Clercq E; Datema R; Werner G
    J Virol; 1996 Feb; 70(2):689-96. PubMed ID: 8551604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
    Bleul CC; Farzan M; Choe H; Parolin C; Clark-Lewis I; Sodroski J; Springer TA
    Nature; 1996 Aug; 382(6594):829-33. PubMed ID: 8752280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist.
    Schols D
    Verh K Acad Geneeskd Belg; 1999; 61(4):551-64. PubMed ID: 10500476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins.
    Balzarini J; Van Laethem K; Hatse S; Vermeire K; De Clercq E; Peumans W; Van Damme E; Vandamme AM; Bölmstedt A; Schols D
    J Virol; 2004 Oct; 78(19):10617-27. PubMed ID: 15367629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.
    Kozak SL; Platt EJ; Madani N; Ferro FE; Peden K; Kabat D
    J Virol; 1997 Feb; 71(2):873-82. PubMed ID: 8995603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
    Kanbara K; Sato S; Tanuma J; Tamamura H; Gotoh K; Yoshimori M; Kanamoto T; Kitano M; Fujii N; Nakashima H
    AIDS Res Hum Retroviruses; 2001 May; 17(7):615-22. PubMed ID: 11375057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
    Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
    AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.